GovChime
Notice ID: 32d26ab4328cd3e75a19809d7d95120fCombined Synopsis/Solicitation

65--Procurement of DNA-based H1N1 vaccine, using Vaxfectin adjuvant and VCL-10551 plasmid backbone, to conduct animal immunogenicity studies and human clinical studies

Archived on October 16, 2009. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
12:00 AM UTC−05:00
Posted
August 10, 2009
Notice type
Combined Synopsis/Solicitation
Set-aside
Small Business Set Aside - Total
NAICS
325414: Biological Product (except Diagnostic) Manufacturing
Agency
Department of WarDepartment of the Army

Notice details

Office
W6QK ACC-APG NATICK
Place of performance
RDECOM Acquisition Center - Natick ATTN: AMSRD-ACC-N, Natick Contracting Division (R and BaseOPS), Building 1, Kansas Street Natick MA 01760-5011 US
PSC
65: MEDICAL/DENTAL/VETERINARY EQPT/SUPP
Last updated
Sep 25, 2026

Identifiers

Solicitation number
W911QY09R0059
Notice ID
32d26ab4328cd3e75a19809d7d95120f

Description

This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and an additional written solicitation will not be issued. The U. S. Army RDECOM Contracting Center, Natick Contracting Division, Natick, MA on behalf of the Naval Medical Research Center (NMRC) has a requirement for the acquisition of H1N1 vaccine. The Government anticipates one FFP award, however it reserves the right to make multiple awards or no award. The contractor will produce and vial Good Manufacturing Process pDNA using the VCL-10551 plasmid that encodes swine-origin influenza virus (SOIV) strain A/California/04/09 (H1N1) hemagglutin (H1 pDNA). Test lots of the pDNA must be adjuvanted with Vaxfectin and tested in mice and rabbits using needle and syringe delivery and demonstrate immunogenicity in both species via a hemmagglutin inhibition assay. The contractor must prepare and submit an IND application for a H1 pDNA-Vaxfectin vaccine to the FDA and must agree to serve as the sponsor of a Phase I clinical trial in humans. The contractor must also develop an immunoassay to evaluate human clinical samples. The reason that both Vaxfectin(r) and VCL-10551 must be used is that they have already shown safety, tolerability and immunogenicity in animals and humans in an H5 influenza vaccine under an Investigational New Drug (IND) Phase I clinical trial by standard needle and syringe delivery methods. Vaxfectin(r) has also been shown to enhance immune responses in other DNA vaccines. Therefore, the purpose of the work to be performed under this contract is to rapidly produce a novel H1 DNA-Vaxfectin vaccine and IND for the purpose of assessing safety, tolerability and immunogenicity in a Phase I clinical trial. The potential total contract value is estimated $1,250,000 over a one year period. The estimated start date is September 2009. This procurement is a 100% small business set aside under NAICS code 325414. The small business size standard for this procurement is a firm with average monthly employee count, including all affiliates, for the last 12 months not in excess of 500 employees. The Request-For-Proposals (RFP)is attached to this announcement. Although the attached RFP states that proposals must be received by 08/15/2009, offerors have UNTIL 02:00 PM EST ON MONDAY, 08/17/2009 to submit proposals; proposals should be submitted electronically via email to david.w.mark@us.army.mil. Proposals received after 02:00 PM EST ON MONDAY, 08/17/2009 will not be considered. Any questions must be sent via e-mail to david.w.mark@us.army.mil. No phone calls or FAXes will be accepted. The acquisition is utilizing Federal Acquisition Regulation (FAR) Parts 12 and 13.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Primary Contact

David W. Mark, 508-233-4367 RDECOM Acquisition Center - Natick

Documents

No documents available.

Lifecycle

Solicitation:W911QY09R0059
  1. Combined Synopsis
  1. Combined SynopsisCurrentAug 10, 2009

    65--Procurement of DNA-based H1N1 vaccine, using Vaxfectin adjuvant and VCL-10551 plasmid backbone, to conduct animal immunogenicity studies and human clinical studies

    Notice 32d26ab4328cd3e75a19809d7d95120f on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline

Additional Details

Solicitation Number

W911QY09R0059

Archive Date

Oct 16, 2009

Office Address

NATICK, MA, 01760-5011